CHANGES OF mRNA CASPASE-3 AFTER FIRST CYCLE OF CHEMOTHERAPY AS BIOMARKER ASSOCIATE TO CHEMOTHERAPY NEGATIVE RESPONSE IN LOCALLY ADVANCED BREAST CANCER

  • I. K. Widiana Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
  • I. B. T. Wibawa Manuaba Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
  • K. Siki Kawiyana Division of Orthopaedic and Traumatology, Faculty of Medicine, Udayana University/Sanglah General Hospital, Bali-Indonesia
  • I W. P. Sutirta Yasa Department of Clinical Pathology, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia

Abstract

Background: Problems caused by behaviour of biology molecular in locally advanced breast cancer still unpredictable. This study aims to identify the mRNA caspase-3 as a predictive biomarker associated to chemotherapy sensitivity following neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer. Methods: Open biopsy before and core biopsy after first cycle neoadjuvant chemotherapy of 62 locally advanced breast cancer patients was analysed for mRNA caspase-3 by Reverse Transcription - Polymerase Chain Reaction (RT-PCR) and this was correlate with response to NAC using American Joint Committee on Cancer (AJCC) creteria. Results: The total mean of mRNA caspase-3 expression before chemotherapy was 12.51±3.03 and after chemotherapy was 11.64±3.13. Negative response to chemotherapy was 44 (70.96%) and positive response was 18 (29.03%). The result of data with Phi and Cramer’s V analysed showed that decrease of mRNA caspase-3 after chemotherapy first cycle as a risk factor to chemotherapy negative response in patients with locally advanced breast cancer was significantly (p = 0.007). Conclusion: Decrease of mRNA caspase-3 after chemotherapy first cycle correlated with chemotherapy negative response in patients with lacally advanced breast cancer.

Downloads

Download data is not yet available.

Author Biographies

I. K. Widiana, Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
I. B. T. Wibawa Manuaba, Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
Division of Surgical Oncology, Department of General Surgery, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
K. Siki Kawiyana, Division of Orthopaedic and Traumatology, Faculty of Medicine, Udayana University/Sanglah General Hospital, Bali-Indonesia
Division of Orthopaedic and Traumatology, Faculty of Medicine, Udayana University/Sanglah General Hospital, Bali-Indonesia
I W. P. Sutirta Yasa, Department of Clinical Pathology, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
Department of Clinical Pathology, Faculty of Medicine Udayana University/Sanglah General Hospital, Bali-Indonesia
Published
2015-08-17
How to Cite
WIDIANA, I. K. et al. CHANGES OF mRNA CASPASE-3 AFTER FIRST CYCLE OF CHEMOTHERAPY AS BIOMARKER ASSOCIATE TO CHEMOTHERAPY NEGATIVE RESPONSE IN LOCALLY ADVANCED BREAST CANCER. BALI MEDICAL JOURNAL, [S.l.], v. 4, n. 2, aug. 2015. ISSN 2302-2914. Available at: <https://ojs.unud.ac.id/index.php/bmj/article/view/21700>. Date accessed: 24 nov. 2024.
Section
Articles

Keywords

mRNA; caspase-3; neoadjuvant; chemotherapy; locally advanced breast cancer.